Customize your JAMA Network experience by selecting one or more topics from the list below.
Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In the Viewpoint entitled “Drugs for Macular Degeneration, Price Discrimination, and Medicare’s Responsibility Not to Overpay” published in the July 2, 2014, issue of JAMA (2014;312:23-24. doi:10.1001/jama.2014.6672), the description of ranibizumab as the Fab portion of bevacizumab in the second paragraph was not accurate. The sentence should have read: “After bevacizumab was introduced, the manufacturer, Genentech, received approval from the US Food and Drug Administration (FDA) for a genetically engineered variant of the Fab portion of bevacizumab to be used in small doses intraocularly to treat neovascular AMD.” The article was corrected online.
Drug Derivation Clarified. JAMA. 2014;312(19):2045. doi:10.1001/jama.2014.14363
Create a personal account or sign in to: